Company Overview
Company Type: Private Company
Website: www.odanlab.com
Number of Employees: 100
Year Founded: 1974
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Odan Laboratories Ltd., a pharmaceutical company, researches and develops medicines for gastroenterology, dermatology, and ophthalmics. It also develops various specialty and generic pharmaceuticals. The company provides dermatological preparations that include treatments for various dermatoses, such as diabetic skin conditions, topical skin infections, nail dystrophies, acne vulgaris, psoriasis, and xerosis. It also offers gastroenterology products that include Purg-Odan, an oral purgative; laxatives Citrodan oral solution; Selax capsules and Bisacodyl-Odan tablets; and anorectal therapy products, such as Anodan-HC, Proctodan-HC, and Proctol (ointments and suppositories). The company distributes its products to retail pharmacies, hospitals, government institutions, clinics, and pharmaceutical wholesalers in Canada. It also exports its products to Eastern Europe, South East Asia, the Pacific Rim, North Africa, the GCC, Latin America, and South America. The company was founded in 1974 and is headquartered in Pointe-Claire, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 38.6
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 100
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Kaminsky, Howard
President


Primary Industry Classification
Pharmaceuticals


Primary Office Location
325 Stillview Avenue | Pointe-Claire, QC | H9R 2Y6 | Canada
Phone: 514-428-1628   Fax: 514-428-9783


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Verlyx Pharma Inc
 As of December 30, 2018, Verlyx Pharma Inc operates as a subsidiary of Odan Laboratories Ltd.

United States and Canada
Pharmaceuticals
-
-
-
Asmacure Ltée
Asmacure Ltée, a clinical-stage biopharmaceutical company, develops proprietary molecules that target cholinergic receptors for the treatment of inflammation (primarily pulmonary airway diseases). It develops ASM-024 for the treatment of moderate asthma and chronic obstructive pulmonary disease with a dry powder for inhalation formulation. The company was founded in 2002 and is based in Quebec City, Canada. As of August 19, 2015, Asmacure Ltée operates as a subsidiary of Odan Laboratories Ltd.

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-30-2018
Dec-30-2018
Merger/Acquisition
Buyer
Verlyx Pharma Inc
Odan Laboratories Ltd.

-
Aug-19-2015
Aug-19-2015
Merger/Acquisition
Buyer
Asmacure Ltée
Odan Laboratories Ltd.
Domain Associates, L.L.C.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Dec-30-2018
M&A Transaction Closings
Odan Laboratories Ltd. acquired Verlyx Pharma Inc.
Aug-19-2015
M&A Transaction Closings
Odan Laboratories Ltd. acquired Asmacure Ltée.
Nov-12-2012
Company Conference Presentations
Odan Laboratories Ltd. Presents at BIO-Europe 2012, Nov-12-2012
Oct-31-2011
Company Conference Presentations
Odan Laboratories Ltd. Presents at 17th Annual BIO Europe 2011, Oct-31-2011


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 21, 2023 04:11 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
47
GlobalData

Jun 16, 2023 02:56 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
47
GlobalData

Mar 16, 2023 03:40 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
47
GlobalData

Dec 15, 2022 12:16 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
47
GlobalData

Sep 19, 2022 08:46 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
47
GlobalData

Jun 16, 2022 01:02 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
47
GlobalData

Mar 14, 2022 02:39 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
47
GlobalData

Dec 14, 2021 02:30 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
21
GlobalData

Sep 15, 2021 02:57 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
15
GlobalData

Jun 14, 2021 09:20 AM
Odan Laboratories Ltd.
Odan Laboratories Ltd
Reports
15


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Kaminsky, Howard
President
514-428-1628
514-428-9783
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
